Septerna, Inc. Files for IPO
Ticker: SEPN · Form: S-1 · Filed: Oct 2, 2024 · CIK: 1984086
Sentiment: neutral
Topics: ipo, biotech, registration-statement
TL;DR
Septerna Inc. just filed for an IPO, get ready for some biotech action.
AI Summary
Septerna, Inc., a biopharmaceutical company, filed an S-1 registration statement on October 2, 2024, to offer its securities. The company is based in South San Francisco, California, and is incorporated in Delaware. Jeffrey Finer, M.D., Ph.D. serves as President and Chief Executive Officer.
Why It Matters
This S-1 filing indicates Septerna, Inc.'s intention to go public, which could provide significant capital for its drug development pipeline and potentially impact the biotechnology sector.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company filing for an IPO, Septerna faces inherent risks related to drug development, clinical trials, regulatory approval, and market competition.
Key Players & Entities
- Septerna, Inc. (company) — Registrant
- October 2, 2024 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- 2834 (sic_code) — Pharmaceutical Preparations
- 843891440 (irs_number) — IRS Employer Identification No.
- 250 EAST GRAND AVENUE, SUITE 65 (address) — Business Address
- SOUTH SAN FRANCISCO (city) — Business Address City
- CA (state) — Business Address State
- 94080 (zip_code) — Business Address Zip
- 650-338-3533 (phone_number) — Business Phone
FAQ
What is the primary business of Septerna, Inc.?
Septerna, Inc. is a biopharmaceutical company focused on developing therapies, as indicated by its SIC code 2834 for Pharmaceutical Preparations.
When did Septerna, Inc. file its S-1 registration statement?
Septerna, Inc. filed its S-1 registration statement on October 2, 2024.
Where is Septerna, Inc. headquartered?
Septerna, Inc. is headquartered at 250 East Grand Avenue, Suite 65, South San Francisco, California 94080.
Who is the President and CEO of Septerna, Inc.?
Jeffrey Finer, M.D., Ph.D. is the President and Chief Executive Officer of Septerna, Inc.
What is the state of incorporation for Septerna, Inc.?
Septerna, Inc. is incorporated in Delaware.
Filing Stats: 4,324 words · 17 min read · ~14 pages · Grade level 16 · Accepted 2024-10-02 16:22:39
Key Financial Figures
- $125 billion — ombined global revenue of approximately $125 billion in 2023. Despite the pharmacological an
- $2.0 billion — ptoms. Despite reaching global sales of $2.0 billion in 2022, TEPEZZA requires several intra
- $18.4 billion — marketed by Eli Lilly and Company) were $18.4 billion and $5.3 billion, respectively. As a cl
- $5.3 b — lly and Company) were $18.4 billion and $5.3 billion, respectively. As a class, the ma
- $36 billion — GLP-1 and GLP-1/GIP products generated $36 billion in global sales in 2023. Despite these
Filing Documents
- d762905ds1.htm (S-1) — 2682KB
- d762905dex31.htm (EX-3.1) — 113KB
- d762905dex33.htm (EX-3.3) — 69KB
- d762905dex41.htm (EX-4.1) — 146KB
- d762905dex101.htm (EX-10.1) — 202KB
- d762905dex1017.htm (EX-10.17) — 428KB
- d762905dex1018.htm (EX-10.18) — 20KB
- d762905dex211.htm (EX-21.1) — 1KB
- d762905dex231.htm (EX-23.1) — 1KB
- d762905dexfilingfees.htm (EX-FILING FEES) — 15KB
- g762905g00b98.jpg (GRAPHIC) — 118KB
- g762905g00w02.jpg (GRAPHIC) — 33KB
- g762905g01n96.jpg (GRAPHIC) — 209KB
- g762905g02n01.jpg (GRAPHIC) — 234KB
- g762905g02n07.jpg (GRAPHIC) — 90KB
- g762905g05g90.jpg (GRAPHIC) — 118KB
- g762905g10t06.jpg (GRAPHIC) — 215KB
- g762905g14g14.jpg (GRAPHIC) — 58KB
- g762905g15a01.jpg (GRAPHIC) — 136KB
- g762905g19m19.jpg (GRAPHIC) — 133KB
- g762905g30c65.jpg (GRAPHIC) — 190KB
- g762905g35e11.jpg (GRAPHIC) — 114KB
- g762905g38i22.jpg (GRAPHIC) — 154KB
- g762905g43d06.jpg (GRAPHIC) — 113KB
- g762905g46d29.jpg (GRAPHIC) — 369KB
- g762905g59y26.jpg (GRAPHIC) — 156KB
- g762905g69v12.jpg (GRAPHIC) — 95KB
- g762905g72w39.jpg (GRAPHIC) — 203KB
- g762905g73h34.jpg (GRAPHIC) — 196KB
- g762905g76a01.jpg (GRAPHIC) — 56KB
- g762905g78p09.jpg (GRAPHIC) — 160KB
- g762905g98o86.jpg (GRAPHIC) — 130KB
- g762905g99m62.jpg (GRAPHIC) — 127KB
- 0001193125-24-231178.txt ( ) — 8310KB
Risk Factors
Risk Factors 14 Special Note Regarding Forward-Looking Statements 94
Use of Proceeds
Use of Proceeds 97 Dividend Policy 99 Capitalization 100
Managements Discussion and Analysis of Financial Condition and Results
Managements Discussion and Analysis of Financial Condition and Results of Operations 105
Business
Business 124 Management 181
Executive Compensation
Executive Compensation 193 Page Director Compensation 207 Certain Relationships and Related Party Transactions 210 Principal Stockholders 214
Description of Capital Stock
Description of Capital Stock 217 Shares Eligible For Future Sale 223 Material U.S. Federal Income Tax Considerations For Non-U.S. Holders of Common Stock 225
Underwriting
Underwriting 230 Legal Matters 242 Experts 242 Where You Can Find More Information 242 Index to Financial Statements F-1 We have not, and the underwriters have not, authorized anyone to provide any information or to make any representation other than those contained in this prospectus, any amendment or supplement to this prospectus or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the shares of our common stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus, any amendment or supplement to this prospectus or any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside the United States. i Table of Contents MARKET AND INDUSTRY DATA Market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental publications, reports by market research firms, including, but not limited to, Clarivate , or other independent sources that we believ